(Albany, US) DelveInsight has launched a new report on Nonalcoholic Steatohepatitis Epidemiology
DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH) Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Nonalcoholic Steatohepatitis (NASH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.
View Free Sample Page:- https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-epidemiology-forecast
Nonalcoholic Steatohepatitis Epidemiology
The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death. DelveInsight’s estimations suggests that of the total diagnosed patients in the United States, F4 accounts for the maximum number in the patient pool (~60%), while F0 had least reported cases. This is due to the nature of the disease to keep on progressing over time, thereby leading to addition of number of patients from early stages of NASH to those in advanced stages.
Nonalcoholic Steatohepatitis Key Facts
Nonalcoholic Steatohepatitis Report Scope
Download Free Sample Page: – https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-epidemiology-forecast
Table of content
1. Key Insights
2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)
3. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/